Partnering for a healthier planet: Our carbon reduction journey
At Centrient Pharmaceuticals, we view decarbonisation as a key element of our ESG strategy and that supports long-term resilience, regulatory readiness, and stakeholder trust.
Greenhouse gas (GHG) emissions—such as carbon dioxide, methane, and nitrous oxide—are key contributors to global warming. For the pharmaceutical industry, managing these emissions are essential not only for environmental stewardship but also for maintaining the integrity of healthcare supply chains.
Our approach is comprehensive. We assess and address emissions across our operations (Scope 1 and 2) and throughout our value chain (Scope 3), including suppliers, logistics, and product use. This full-spectrum view allows us to identify meaningful opportunities for reduction and collaboration. For instance, our Scope 3 emissions account for approximately 60% of our total carbon footprint, with the largest share coming from purchased goods and services and fuel- and energy-related activities. That’s why we work closely with our suppliers to track, monitor, and reduce these emissions—ensuring our entire supply chain contributes to our climate goals.
Centrient’s climate targets are validated by the Science Based Targets initiative (SBTi), as we strive to ensure our goals are grounded in climate science and aligned with global efforts to limit warming to 1.5°C. We follow internationally recognised frameworks such as the GHG Protocol, enabling transparent, consistent, and credible reporting.
Reducing emissions is not just about compliance—it’s about seeking to lead the way. By transitioning to cleaner energy sources, engaging suppliers, and embedding climate action into our strategy, we’re building a future where pharmaceutical innovation and environmental responsibility go hand in hand.
Together, we can accelerate the shift to a low-carbon healthcare system—one step, one site, one partnership at a time.
Centrient's commitments
To drive meaningful progress in reducing our Scope 1, Scope 2, and Scope 3 greenhouse gas emissions, Centrient remains committed to advancing our climate transition plan. This plan is aligned with our near-term climate reduction targets under the Science-Based Targets initiative (SBTi) and reflects the decarbonization trajectory outlined in the Paris Agreement, aimed at limiting global temperature rise to below 1.5°C. We have the following targets set in our ESG strategy:
- Reduce Scope 1 and 2 GHG emissions of 46.2% by 2031 from the 2022 base year.
- Reduce Scope 3 GHG emissions from purchased goods and services and fuel and energy-related activities of 27.5% by 2031 from the 2022 base year.
What we achieved in 2024
- Reducing our Scope 1 and 2 emissions by 8% from the 2022 base year.
- While our scope 3 emissions increased compared to the 2022 base year (purchased goods and services and fuel and energy-related activities categories), we are committed to reducing these by our target date, by engaging with our key suppliers, through the supplier engagement program established in 2025.
- Reducing emissions at several of our manufacturing sites via transitioning to more sustainable fuel sources, such as replacing furnace oil with natural gas in Toansa, increasing the share of renewable electricity used in Yushu, and improving off-gas treatments to reduce volatile organic components across all sites.